Historial de carrera de David Skarinsky
Antiguos cargos conocidos de David Skarinsky.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| OTONOMY | Director Técnico/Científico/I+D | 01/01/2020 | 01/12/2022 |
| NABRIVA THERAPEUTICS PLC | Corporate Officer/Principal | - | - |
Abide Therapeutics, Inc.
 Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - | - |
Formación de David Skarinsky.
| Amherst College | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 4 |
| Irlanda | 2 |
Operativa
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| NABRIVA THERAPEUTICS PLC | Health Technology |
| Empresas privadas | 2 |
|---|---|
Otonomy, Inc.
 Otonomy, Inc. BiotechnologyHealth Technology Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. | Health Technology |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Health Technology |
- Bolsa de valores
- Insiders
- David Skarinsky
- Experiencia
